A5047396858- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Phagocytosis and Immune Regulation
- Economic and Financial Impacts of Cancer
- Acute Lymphoblastic Leukemia research
- Galectins and Cancer Biology
- CAR-T cell therapy research
- Nuclear Structure and Function
- COVID-19 and healthcare impacts
- Glycosylation and Glycoproteins Research
- Health Systems, Economic Evaluations, Quality of Life
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Immunodeficiency and Autoimmune Disorders
- Telemedicine and Telehealth Implementation
- RNA modifications and cancer
- Head and Neck Cancer Studies
- Childhood Cancer Survivors' Quality of Life
- RNA Research and Splicing
- Complement system in diseases
- Medication Adherence and Compliance
- Genetic factors in colorectal cancer
- CNS Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Biosimilars and Bioanalytical Methods
Flatiron Health (United States)
2021-2024
The Barbara Ann Karmanos Cancer Institute
2016-2024
Wayne State University
2016-2024
University of Chicago
2017
University of Michigan
2012-2016
Michigan Medicine
2014
Michigan United
2014
Dana-Farber Cancer Institute
2013
Chronic lymphocytic leukemia (CLL)-associated gene mutations that influence CLL cell fitness and chemotherapy resistance should increase in clonal representation when measured before therapy at relapse.To uncover associated with relapse, we have performed whole-exome sequencing a discovery cohort of 61 relapsed patients identifying 86 recurrently mutated genes. The variant allele fractions (VAF) 19 genes ≥3 cases were 53 paired pre- posttreatment samples sorted to purity using panel-based...
The identification of gene mutations and structural genomic aberrations that are critically involved in chronic lymphocytic leukemia (CLL) pathogenesis is still evolving. One may postulate driver lesions with effects on CLL cell proliferation, apoptosis thresholds, or chemotherapy resistance should increase frequency over time when measured sequentially a large cohort.We sampled well-characterized cohort at mean 4 years between samplings acquired copy number (aCNA) LOH using...
Background The incidence of nasopharyngeal carcinoma (NPC) has been historically low in the United States. Although etiological factors differ by histological subtype, Epstein‐Barr virus is accepted as primary risk factor for nonkeratinizing NPC. In light changing epidemiology viral‐associated cancers, it important to evaluate temporal NPC Methods Incidence and survival data from 1973 through 2015 were obtained Surveillance, Epidemiology, End Results program. Stratified analyses conducted...
Monocytes and their progeny are abundant constituents of the tumor microenvironment in lymphoproliferative disorders, including chronic lymphocytic leukemia (CLL). Monocyte-derived cells, nurse-like cells (NLC) CLL, promote lymphocyte proliferation survival, confer resistance to chemotherapy, associated with more rapid disease progression. Colony-stimulating factor-1 receptor (CSF-1R) regulates homeostatic survival tissue-resident macrophages. Therefore, we sought determine whether CSF-1R is...
The nuclear exporter protein exportin-1 (XPO1) is overexpressed in non-Hodgkin lymphoma (NHL) and correlates with poor prognosis. We evaluated enhancing R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) activity NHL by targeted inhibition of XPO1 using the selective inhibitor export (SINE) compounds.We antitumor SINE compounds combination CHO chemotherapy vitro vivo. Newly diagnosed patients a phase I dose-escalation study received for 6 cycles weekly selinexor (60,...
Abstract Background Laboratory testing and treatments for chronic lymphocytic leukemia (CLL) have changed dramatically within the last decade. The authors evaluated changes in patterns of real‐world treatment over time by comparing 2 population‐based cohorts. Methods National Cancer Institute–sponsored Patterns Care study was conducted among patients with CLL who were sampled from 14 Surveillance, Epidemiology, End Results (SEER) program registries. Demographics, testing, data abstracted...
Importance The COVID-19 pandemic has led to a reduction in routine in-person medical care; however, it is unknown whether there have been any changes visit rates among patients with hematologic neoplasms. Objective To examine associations between the and visits telemedicine use undergoing active treatment for Design, Setting, Participants Data this retrospective observational cohort study were obtained from nationwide electronic health record–derived, deidentified database. neoplasms who had...
Purpose Chronic Lymphocytic Leukemia (CLL) is defined by a perturbed B-cell receptor-mediated signaling machinery. We aimed to model differential behavior between B cells from CLL and healthy individuals pinpoint modes of dysregulation. Experimental Design developed an experimental methodology combining immunophenotyping, multiplexed phosphospecific flow cytometry, multifactorial statistical modeling. Utilizing patterns network covariance, we modeled BCR in 67 patients using Partial Least...
7512 Background: The combination of Pola-R-Len may enhance anti-tumor response in R/R DLBCL. We report the primary analysis DLBCL cohort a Phase 1b/2 study (GO29834; NCT02600897). Methods: Pts received induction with 6 x 28-Day (D) cycles (C) of: Pola 1.8mg/kg intravenous (IV; C1−6: D1); R 375mg/m 2 IV (C1−6: D1) and oral Len 10–20mg (dose escalation) or recommended dose (RP2D) daily on D1–21. at end (EOI) months (mo) consolidation (D1 every mo) 10mg (D1–21 monthly). Primary endpoints were...
High-cost drugs impose a financial burden on patients with cancer. Karmanos Specialty Pharmacy (KSP) developed process to automate assistance (FA) applications decrease patient drug cost. We evaluate the outcomes of this program cost and payers.This is an observational, retrospective study KSP claims data set from January December 2019, accessed by 13 statewide cancer centers within Michigan. Drug patients, payers, FA (funds lower cost), types were obtained. A subset analysis was performed...
3030 Background: CD47 is an immune checkpoint that binds signal regulatory protein alpha (SIRPα) and delivers a "do not eat" to suppress macrophage phagocytosis. Cancer cells frequently overexpress escape surveillance. TTI-622 fusion consisting of the CD47-binding domain human SIRPα linked Fc region IgG4. acts as decoy receptor, preventing from delivering its inhibitory enabling activation anti-cancer activity via pro-phagocytic signals present on cancer cells. Unlike many CD47-blocking...
The ASCO Value Framework calculates the value of cancer therapies. Given costly novel therapeutics for chronic lymphocytic leukemia, we used framework to compare net health benefit (NHB) and cost within Medicare all regimens listed in National Comprehensive Cancer Network (NCCN) guidelines.
Patients with high cost-sharing of tyrosine kinase inhibitors (TKIs) experience delays in treatment for chronic myeloid leukemia (CML). To the authors' knowledge, clinical outcomes among and costs patients not receiving TKIs are well defined.Using Surveillance, Epidemiology, End Results (SEER)-Medicare database, authors evaluated differences TKI initiation, health care use, cost, survival CML continuous Medicare Parts A B Part D coverage who were diagnosed between 2007 2015.A total 941...
TPS2667 Background: SUMOylation, a posttranslational modification analogous to ubiquitination, attaches small, ubiquitin-like modifier (SUMO) target proteins. SUMOylation plays central role in regulating type I interferon (IFN-I)-dependent innate response and functions constrain the immune response, which can impair tumor surveillance. TAK-981 is first-in-class, small-molecule inhibitor of SUMO-activating enzyme subunit 2 (SAE2). Inhibition SAE2 by disrupts thereby allowing system...
1 Background: Financial toxicity, the burden of treatment cost, affects 30-50% people with cancer in US. Although experts recommend patients and oncologists discuss cost to identify who need assistance, discussions occur fewer than half discussions. We pilot-tested feasibility efficacy Discussions Cost (DISCO) App, a patient communication intervention designed improve other financial toxicity-related outcomes during following oncology consultations. The DISCO App provides an individualized...